抗真菌薬の市場規模、シェア、動向分析レポート：薬剤クラス別、適応症別、剤形別、流通チャネル別、地域別、セグメント別予測、2024年～2030年

抗真菌薬市場の成長と動向：

Grand View Research社の最新レポートによると、世界の抗真菌薬市場規模は2030年までに205億2,000万米ドルに達する見込みです。

同市場は2024年から2030年にかけてCAGR 3.8%で拡大する見込みです。世界の真菌感染症の罹患率の増加が、同市場の成長を後押しする主要因となっています。また、免疫抑制剤や抗悪性腫瘍剤、補綴器具や移植片、広域抗生物質の採用が増加した結果、近年真菌感染症の発生率が増加しています。

2017年に米国疾病予防管理センターが発表した統計によると、毎年、新たに22万人近くが脳感染症であるクリプトコッカス髄膜炎に罹患し、世界中で年間18万1,000人が死亡していると推定されています。死亡者のほとんどは、HIV/AIDSの高い有病率のため、サハラ以南のアフリカで報告されています。このことは、世界中で真菌感染症が多発していることから、抗真菌薬の潜在的な需要があることを示しています。

多くの国の政府当局は、COVID-19の蔓延を抑えるために全国的な封鎖を命じた。同様に、世界各国の保健システムもサプライチェーンの維持に苦労していました。サプライチェーンの遅れは抗真菌薬の需要にも影響を及ぼしています。高齢者はHIVやがんなどの感染症や慢性疾患にかかりやすいため、世界の高齢者人口の増加は日和見真菌感染症を治療するための抗真菌薬の需要をかき立てる可能性が高いです。診断が困難で死亡率や罹患率が高い真菌感染症が増加していることから、2030年まで抗真菌剤の需要は堅調に推移すると予測されます。

抗真菌薬市場のレポートハイライト

• アゾール系薬剤クラス別が市場を独占し、2023年の売上高シェアは47.6%に達しました。この優位性は、ノキサフィル、ブフェンド、ジフルカン、クレセンバなどの主要治療薬の影響によるものです。
• カンジダ症は、免疫不全患者における罹患率の上昇と感染再発率の高さから、2023年に最大の市場シェアを占めました。
• アスペルギルス症は予測期間中に大きなCAGRを記録する見込みです。アスペルギルス症は、アスペルギルス症と呼ばれるカビによって引き起こされる感染症で、通常は呼吸器系を侵します。
• 2023年は経口薬の剤形が市場をリードしました。これは、特定の抗真菌薬が適切な摂取を確実にするために経口投与用に設計されていることに起因します。
• 病院薬局が2023年の市場をリード。病院薬局は、重要な医薬品への即時アクセスを確保する上で重要な役割を果たしています。病院薬局は外来患者と入院患者の両方にサービスを提供し、真菌感染症のシームレスな治療を促進します。
• 北米が市場を独占し、2023年には40.9%のシェアを占めました。この地域の優位性は、高度に発達したヘルスケアインフラ、手頃な価格、意識の高まりに起因しています。
• アジア太平洋地域は、予測期間中に大きな成長が見込まれます。これは、対象人口が多いこと、ヘルスケア施設が新興国市場を開拓していること、主要市場プレーヤーによる投資が増加していることによる。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 抗真菌薬市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 抗真菌薬市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 抗真菌薬市場：薬剤クラスの推定・動向分析

• 薬剤クラスの市場シェア、2023年と2030年
• セグメントダッシュボード
• 薬剤クラス別の世界の抗真菌薬市場の見通し
• 以下の市場規模、予測および動向分析、2018年から2030年まで
  • アゾール
  • エキノカンジン
  • ポリエン
  • アリルアミン
  • その他

第5章 抗真菌薬市場：適応症の推定・動向分析

• 適応症の市場シェア、2023年および2030年
• セグメントダッシュボード
• 適応症別の世界の抗真菌薬市場の見通し
• 以下の市場規模、予測および動向分析、2018年から2030年まで
  • 皮膚糸状菌症
  • アスペルギルス症
  • カンジダ症
  • その他

第6章 抗真菌薬市場：剤形の推定・動向分析

• 剤形市場シェア、2023年および2030年
• セグメントダッシュボード
• 剤形別の世界の抗真菌薬市場の見通し
• 以下の市場規模、予測および動向分析、2018年から2030年まで
  • 経口薬
  • 軟膏
  • 粉末
  • その他

第7章 抗真菌薬市場：流通チャネルの推定・動向分析

• 流通チャネル市場シェア、2023年と2030年
• セグメントダッシュボード
• 流通チャネル別の世界の抗真菌薬市場の見通し
• 以下の市場規模、予測および動向分析、2018年から2030年まで
  • 病院薬局
  • 小売薬局
  • その他

第8章 抗真菌薬市場：地域の推定・動向分析

• 地域市場シェア分析、2023年および2030年
• 地域市場ダッシュボード
• 世界の地域市場のスナップショット
• 市場規模と予測トレンド分析、2018年から2030年：
• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 会社/競合の分類
• ベンダー情勢
  • 主要ディストリビューターとチャネルパートナーのリスト
  • 主要顧客
  • 主要企業シェア分析、2023年
  • NOVARTIS AG
  • PFIZER, INC.
  • BAYER AG
  • SANOFI
  • MERCK &CO., INC.
  • F. GSK PLC
  • ABBOTT
  • GLENMARK
  • ASTELLAS PHARMA, INC.
  • SCYNEXIS INC.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America antifungal drugs market, by region, 2018 - 2030 (USD Million)
• Table 3 North America antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 4 North America antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 5 North America antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 6 North America antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 7 U.S. antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 8 U.S. antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 9 U.S. antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 10 U.S. antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 11 Canada antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 12 Canada antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 13 Canada antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 14 Canada antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 15 Europe antifungal drugs market, by region, 2018 - 2030 (USD Million)
• Table 16 Europe antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 17 Europe antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 18 Europe antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 19 Europe antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 20 Germany antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 21 Germany antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 22 Germany antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 23 Germany antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 24 UK antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 25 UK antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 26 UK antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 27 UK antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 28 France antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 29 France antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 30 France antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 31 France antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 32 Italy antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 33 Italy antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 34 Italy antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 35 Italy antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 36 Spain antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 37 Spain antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 38 Spain antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 39 Spain antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 40 Denmark antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 41 Denmark antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 42 Denmark antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 43 Denmark antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 44 Sweden antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 45 Sweden antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 46 Sweden antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 47 Sweden antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 48 Norway antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 49 Norway antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 50 Norway antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 51 Norway antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 52 Asia Pacific antifungal drugs market, by region, 2018 - 2030 (USD Million)
• Table 53 Asia Pacific antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 54 Asia Pacific antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 55 Asia Pacific antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 57 China antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 58 China antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 59 China antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 60 China antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 61 Japan antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 62 Japan antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 63 Japan antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 64 Japan antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 65 India antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 66 India antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 67 India antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 68 India antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 69 South Korea antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 70 South Korea antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 71 South Korea antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 72 South Korea antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 73 Australia antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 74 Australia antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 75 Australia antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 76 Australia antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 77 Thailand antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 78 Thailand antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 79 Thailand antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 80 Thailand antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 81 Latin America antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 82 Latin America antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 83 Latin America antifungal drugs market, by application, 2018 - 2030 (USD Million)
• Table 84 Latin America antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 85 Latin America antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 86 Brazil antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 87 Brazil antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 88 Brazil antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 89 Brazil antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 90 Mexico antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 91 Mexico antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 92 Mexico antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 93 Mexico antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 94 Argentina antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 95 Argentina antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 96 Argentina antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 97 Argentina antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 98 MEA antifungal drugs market, by region, 2018 - 2030 (USD Million)
• Table 99 MEA antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 100 MEA antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 101 MEA antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 102 MEA antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 103 South Africa antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 104 South Africa antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 105 South Africa antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 106 South Africa antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 107 Saudi Arabia antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 110 Saudi Arabia antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 111 UAE antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 112 UAE antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 113 UAE antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 114 UAE antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 115 Kuwait antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 116 Kuwait antifungal drugs market, by Indication, 2018 - 2030 (USD Million)
• Table 117 Kuwait antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 118 Kuwait antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Antifungal drugs market: market outlook
• Fig. 14 Antifungal drugs competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Penetration and growth prospect mapping
• Fig. 18 Industry value chain analysis
• Fig. 19 Antifungal drugs market driver impact
• Fig. 20 Antifungal drugs market restraint impact
• Fig. 21 Antifungal drugs market strategic initiatives analysis
• Fig. 22 Antifungal drugs market: Drug Class movement analysis
• Fig. 23 Antifungal drugs market: Drug Class outlook and key takeaways
• Fig. 24 Azoles market estimates and forecast, 2018 - 2030
• Fig. 25 Echinocandins market estimates and forecast, 2018 - 2030
• Fig. 26 Polyenes market estimates and forecast, 2018 - 2030
• Fig. 27 Allylamines market estimates and forecast, 2018 - 2030
• Fig. 28 Others market estimates and forecast, 2018 - 2030
• Fig. 29 Antifungal drugs market: Indication movement Analysis
• Fig. 30 Antifungal drugs market: Indication outlook and key takeaways
• Fig. 31 Dermatophytosis market estimates and forecasts, 2018 - 2030
• Fig. 32 Aspergillosis market estimates and forecasts,2018 - 2030
• Fig. 33 Candidiasis market estimates and forecasts, 2018 - 2030
• Fig. 34 Others market estimates and forecasts,2018 - 2030
• Fig. 35 Antifungal drugs market: Dosage form movement Analysis
• Fig. 36 Antifungal drugs market: Dosage form outlook and key takeaways
• Fig. 37 Oral drugs market estimates and forecasts, 2018 - 2030
• Fig. 38 Ointments market estimates and forecasts,2018 - 2030
• Fig. 39 Powders market estimates and forecasts, 2018 - 2030
• Fig. 40 Others market estimates and forecasts,2018 - 2030
• Fig. 41 Antifungal drugs market: Distribution channel movement Analysis
• Fig. 42 Antifungal drugs market: Distribution channel outlook and key takeaways
• Fig. 43 Hospital pharmacies market estimates and forecasts, 2018 - 2030
• Fig. 44 Retail pharmacies market estimates and forecasts,2018 - 2030
• Fig. 45 Others market estimates and forecasts,2018 - 2030
• Fig. 46 Global antifungal drugs market: Regional movement analysis
• Fig. 47 Global antifungal drugs market: Regional outlook and key takeaways
• Fig. 48 Global antifungal drugs market share and leading players
• Fig. 49 North America market share and leading players
• Fig. 50 Europe market share and leading players
• Fig. 51 Asia Pacific market share and leading players
• Fig. 52 Latin America market share and leading players
• Fig. 53 Middle East & Africa market share and leading players
• Fig. 54 North America: SWOT
• Fig. 55 Europe SWOT
• Fig. 56 Asia Pacific SWOT
• Fig. 57 Latin America SWOT
• Fig. 58 MEA SWOT
• Fig. 59 North America, by country
• Fig. 60 North America
• Fig. 61 North America market estimates and forecasts, 2018 - 2030
• Fig. 62 U.S.
• Fig. 63 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 64 Canada
• Fig. 65 Canada market estimates and forecasts, 2018 - 2030
• Fig. 66 Europe
• Fig. 67 Europe market estimates and forecasts, 2018 - 2030
• Fig. 68 UK
• Fig. 69 UK market estimates and forecasts, 2018 - 2030
• Fig. 70 Germany
• Fig. 71 Germany market estimates and forecasts, 2018 - 2030
• Fig. 72 France
• Fig. 73 France market estimates and forecasts, 2018 - 2030
• Fig. 74 Italy
• Fig. 75 Italy market estimates and forecasts, 2018 - 2030
• Fig. 76 Spain
• Fig. 77 Spain market estimates and forecasts, 2018 - 2030
• Fig. 78 Denmark
• Fig. 79 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 80 Sweden
• Fig. 81 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 82 Norway
• Fig. 83 Norway market estimates and forecasts, 2018 - 2030
• Fig. 84 Asia Pacific
• Fig. 85 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 86 China
• Fig. 87 China market estimates and forecasts, 2018 - 2030
• Fig. 88 Japan
• Fig. 89 Japan market estimates and forecasts, 2018 - 2030
• Fig. 90 India
• Fig. 91 India market estimates and forecasts, 2018 - 2030
• Fig. 92 Thailand
• Fig. 93 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 94 South Korea
• Fig. 95 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 96 Australia
• Fig. 97 Australia market estimates and forecasts, 2018 - 2030
• Fig. 98 Latin America
• Fig. 99 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 100 Brazil
• Fig. 101 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 102 Mexico
• Fig. 103 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 104 Argentina
• Fig. 105 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 106 Middle East and Africa
• Fig. 107 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 108 South Africa
• Fig. 109 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 110 Saudi Arabia
• Fig. 111 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 112 UAE
• Fig. 113 UAE market estimates and forecasts, 2018 - 2030
• Fig. 114 Kuwait
• Fig. 115 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 116 Market share of key market players- Antifungal drugs market

Antifungal Drugs Market Growth & Trends:

The global antifungal drugs market size is expected to reach USD 20.52 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.8% from 2024 to 2030. The increasing incidence of fungal infections worldwide is the key factor stoking the growth of the market. In addition, the rise in the adoption of immunosuppressive and antineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics has resulted in an increased incidence of fungal infections in recent years.

According to statistics published by the Centers for Disease Control and Prevention in 2017, it has been estimated that every year, nearly 220,000 new individuals are affected by cryptococcal meningitis, which is a brain infection and has resulted in 181,000 deaths per year around the world. Most of the deaths were reported in sub-Saharan Africa, due to the high prevalence of HIV/AIDS. This indicates the potential demand for antifungal drugs due to the high prevalence of mycological infections around the globe.

The government authorities in many countries had ordered nationwide lockdowns in order to contain the spread of COVID-19. Similarly, health systems in a number of countries around the world were having trouble maintaining their supply chains. The slowness of the supply chain has also impacted the demand for antifungal medications. As aged people are more prone to infectious diseases and chronic conditions, including HIV and cancer, the rise in the geriatric population worldwide is likely to stir up the demand for antifungals to treat opportunistic fungal infections. The demand for fungistatic agents is estimated to remain strong through 2030 due to mounting cases of fungal infections that are difficult to diagnose, yielding high mortality and morbidity rates.

Antifungal Drugs Market Report Highlights:

• The Azoles drug class segment dominated the market and accounted for a revenue share of 47.6% in 2023. This dominance is attributed to the influence of key therapeutic agents, including noxafil, vfend, diflucan, and cresemba.
• The Candidiasis segment held the largest market share in 2023 due to rising incidence of the disease in immunocompromised patients and high rate of recurrent infections.
• Aspergillosis is expected to register significant CAGR during the forecast period. Aspergillosis is an infection caused by mold called aspergillosis, which usually affects the respiratory system.
• Oral drugs dosage form led the market in 2023. This is attributed to the fact that certain antifungal medications are designed for oral administration to ensure proper ingestion.
• Hospital pharmacies led the market in 2023. Hospital pharmacies play a key role in ensuring immediate access to crucial medications. They serve both out-patient and in-patient services, facilitating the seamless treatment of fungal infections.
• North America dominated the market and accounted for 40.9% share in 2023. This region dominance is attributed to the highly developed healthcare infrastructure, better affordability, and increasing awareness.
• Asia Pacific is anticipated to witness significant growth during the forecast period. This is owing to the presence of large target population, developing healthcare facilities, and increase in investments by leading market players.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Indication
  • 1.2.3. Dosage Form
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Class outlook
  • 2.2.2. Indication outlook
  • 2.2.3. Dosage Form outlook
  • 2.2.4. Distribution Channel outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Antifungal Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing Incidence Of Fungal Infections
    • 3.2.1.2. Increase In Awareness
    • 3.2.1.3. Rising R & D Pertaining To The Development Of Novel Drugs
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Cost Associated With Mrd Testing
    • 3.2.2.2. Complex Regulatory Framework Associated With Mrd Testing
• 3.3. Antifungal Drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Antifungal Drugs Market: Drug Class Estimates & Trend Analysis

• 4.1. Drug Class Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Antifungal Drugs Market by Drug Class Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Azoles
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Echinocandins
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Polyenes
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Allylamines
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Antifungal Drugs Market: Indication Estimates & Trend Analysis

• 5.1. Indication Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Antifungal Drugs Market by Indication Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Dermatophytosis
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Aspergillosis
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Candidiasis
    • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.4. Others
    • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Antifungal Drugs Market: Dosage Form Estimates & Trend Analysis

• 6.1. Dosage Form Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Antifungal Drugs Market by Dosage Form Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Oral Drugs
    • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Ointments
    • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Powders
    • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Others
    • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Antifungal Drugs Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Distribution Channel Market Share, 2023 & 2030
• 7.2. Segment Dashboard
• 7.3. Global Antifungal Drugs Market by Distribution Channel Outlook
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Hospital Pharmacies
    • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Retails Pharmacies
    • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Others
    • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Antifungal Drugs Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.5. North America
  • 8.5.1. U.S.
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. Canada
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Europe
  • 8.6.1. UK
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Germany
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. France
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Italy
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Spain
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Norway
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Sweden
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Regulatory framework/ reimbursement structure
    • 8.6.7.3. Competitive scenario
    • 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.8. Denmark
    • 8.6.8.1. Key country dynamics
    • 8.6.8.2. Regulatory framework/ reimbursement structure
    • 8.6.8.3. Competitive scenario
    • 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Asia Pacific
  • 8.7.1. Japan
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. China
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. India
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Australia
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.5. South Korea
    • 8.7.5.1. Key country dynamics
    • 8.7.5.2. Regulatory framework/ reimbursement structure
    • 8.7.5.3. Competitive scenario
    • 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.6. Thailand
    • 8.7.6.1. Key country dynamics
    • 8.7.6.2. Regulatory framework/ reimbursement structure
    • 8.7.6.3. Competitive scenario
    • 8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. Latin America
  • 8.8.1. Brazil
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. Mexico
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Argentina
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/ reimbursement structure
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.9. MEA
  • 8.9.1. South Africa
    • 8.9.1.1. Key country dynamics
    • 8.9.1.2. Regulatory framework/ reimbursement structure
    • 8.9.1.3. Competitive scenario
    • 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.2. Saudi Arabia
    • 8.9.2.1. Key country dynamics
    • 8.9.2.2. Regulatory framework/ reimbursement structure
    • 8.9.2.3. Competitive scenario
    • 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.3. UAE
    • 8.9.3.1. Key country dynamics
    • 8.9.3.2. Regulatory framework/ reimbursement structure
    • 8.9.3.3. Competitive scenario
    • 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.9.4. Kuwait
    • 8.9.4.1. Key country dynamics
    • 8.9.4.2. Regulatory framework/ reimbursement structure
    • 8.9.4.3. Competitive scenario
    • 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis, By Key Market Participants
• 9.2. Company/Competition Categorization
• 9.3. Vendor Landscape
  • 9.3.1. List of key distributors and channel partners
  • 9.3.2. Key customers
  • 9.3.3. Key company market share analysis, 2023
  • 9.3.4. NOVARTIS AG
    • 9.3.4.1. Company overview
    • 9.3.4.2. Financial performance
    • 9.3.4.3. Product benchmarking
    • 9.3.4.4. Strategic initiatives
  • 9.3.5. PFIZER, INC.
    • 9.3.5.1. Company overview
    • 9.3.5.2. Financial performance
    • 9.3.5.3. Product benchmarking
    • 9.3.5.4. Strategic initiatives
  • 9.3.6. BAYER AG
    • 9.3.6.1. Company overview
    • 9.3.6.2. Financial performance
    • 9.3.6.3. Product benchmarking
    • 9.3.6.4. Strategic initiatives
  • 9.3.7. SANOFI
    • 9.3.7.1. Company overview
    • 9.3.7.2. Financial performance
    • 9.3.7.3. Product benchmarking
    • 9.3.7.4. Strategic initiatives
  • 9.3.8. MERCK & CO., INC.
    • 9.3.8.1. Company overview
    • 9.3.8.2. Financial performance
    • 9.3.8.3. Product benchmarking
    • 9.3.8.4. Strategic initiatives
  • 9.3.9. F. GSK PLC
    • 9.3.9.1. Company overview
    • 9.3.9.2. Financial performance
    • 9.3.9.3. Product benchmarking
    • 9.3.9.4. Strategic initiatives
  • 9.3.10. ABBOTT
    • 9.3.10.1. Company overview
    • 9.3.10.2. Financial performance
    • 9.3.10.3. Product benchmarking
    • 9.3.10.4. Strategic initiatives
  • 9.3.11. GLENMARK
    • 9.3.11.1. Company overview
    • 9.3.11.2. Financial performance
    • 9.3.11.3. Product benchmarking
    • 9.3.11.4. Strategic initiatives
  • 9.3.12. ASTELLAS PHARMA, INC.
    • 9.3.12.1. Company overview
    • 9.3.12.2. Financial performance
    • 9.3.12.3. Product benchmarking
    • 9.3.12.4. Strategic initiatives
  • 9.3.13. SCYNEXIS INC.
    • 9.3.13.1. Company overview
    • 9.3.13.2. Financial performance
    • 9.3.13.3. Product benchmarking
    • 9.3.13.4. Strategic initiatives